From England, this news: GlaxoSmithKline (GSK) attempted to show that the drug Seroxat worked for depressed children despite failed clinical trials.
From last week, you may recall reading on this blog the issues that arise when drugmakers pay or influence medical journals regarding studies or trials of pharma meds.
In this instance, there are claims that GSK-employed ghostwriters influenced "independent" academics.
One email that has surfaced is from a public relations executive working for GSK which said: "Originally we had planned to do extensive media relations surrounding this study until we actually viewed the results ... but essentially the study did not really show it was effective in treating adolescent depression, which is not something we want to publicize."
Go here for the full BBC News report.
